<DOC>
	<DOC>NCT00710268</DOC>
	<brief_summary>Phase I, open label, dual centre, dose finding study to evaluate the safety and tolerability of continuous twice daily oral dosing with AZD2281 when administered in combination with Bevacizumab 10mg/kg given every 2 weeks to patients with advanced solid tumours.</brief_summary>
	<brief_title>Study to Assess Safety &amp; Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Histologically confirmed metastatic cancer, not amenable to surgery or radiation therapy with curative intent Adequate bone marrow, kidney and liver function in accordance with laboratory parameters set out in the protocol Estimated life expectancy of at least 12 weeks Disorders that may put the patient at risk of bleeding, including gastrointestinal perforation, intraabdominal abcess, major surgery of the chest or abdomen, previous haemorrhage, coughing up blood or thrombotic event Hypertension (high blood pressure) or significant cardiovascular disease Hypersensitivity to Chinese hamster ovary cell products or other recombinant or humanised antibodies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>Poly(ADP ribose) polymerases</keyword>
	<keyword>Metastatic Solid Tumours</keyword>
	<keyword>PARP inhibitor</keyword>
</DOC>